Drug development

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Retrieved on: 
Thursday, March 14, 2024
SIV, Data, Combination, EGFR, Property, SPI, Patient, Sale, Attention deficit hyperactivity disorder, Syndrome, Lung cancer, IND, Myelodysplastic syndrome, Bank statement, Investment, Note, European, TNBC, ADHD, GAP, BioLite, DSM-IV codes, GMP, Investigational New Drug, MDS, Common stock, UCSF, NSCLC, Dietary supplement, Research, Good manufacturing practice, Cancer, University, Security (finance), Pancreatic cancer, Drug development, TGA, FDA, Map, Consultant, Variable, Toxicity, Metastasis, Patent, MDD, Triple-negative breast cancer, License, Long-term care, Net, US FDA, Pharmaceutical industry

As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).

Key Points: 
  • As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).
  • The Company entered a cooperation agreement on August 14, 2023, with Zhong Hui Lian He Ji Tuan, Ltd. (“Zhonghui”).
  • On February 06, 2024, ABVC acquired an additional real estate asset via an equity transfer of 703,495 shares at $3.50 per share to develop plant factories for ABVC’s botanical pipeline.
  • ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries.

Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science

Retrieved on: 
Thursday, March 14, 2024
Toxicity, Notifiable disease, TELO, Entrepreneurship, Science, Research, DNA, Ageing, MD, Quality of life, Drug development, Osteoarthritis, Pharmaceutical industry

Telomir’s recent AI-powered research presented in Singapore last month not only supports but amplifies the therapeutic potential of Telomir-1.

Key Points: 
  • Telomir’s recent AI-powered research presented in Singapore last month not only supports but amplifies the therapeutic potential of Telomir-1.
  • Additional AI-driven studies now being conducted to demonstrate Telomir-1's promising therapeutic potential, supporting Telomir’s hypothesis with solid computational evidence.
  • As part of its work, Telomir works with third-party collaborators Frontage Laboratories and InSilicoTrials, each of whom utilize AI in-silico testing models.
  • To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024

Retrieved on: 
Thursday, March 14, 2024
Inflammasome, Obesity, Entrepreneurship, Multiple sclerosis, Inflammation, Death, NLRP3, World Health Organization, ASC, Therapy, Atherosclerosis, Drug development, Pharmaceutical industry

According to the World Health Organization, 3 of 5 people worldwide die due to chronic inflammatory diseases, which are considered the most significant cause of death in the world.

Key Points: 
  • According to the World Health Organization, 3 of 5 people worldwide die due to chronic inflammatory diseases, which are considered the most significant cause of death in the world.
  • WESTON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will participate in a panel discussion titled “Inflammation Illuminated,” at Benzinga’s Virtual Healthcare Summit 2024.
  • He will also address new innovations in drug development to alleviate damaging inflammation.
  • Details regarding Mr. Glover’s panel discussion are as follows:

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, March 13, 2024
Drug development, Patient, CYTH, Niemann–Pick disease, Research, Investment, RFL

NEWARK, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter of fiscal 2024 – and the six months ended January 31, 2024.

Key Points: 
  • NEWARK, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter of fiscal 2024 – and the six months ended January 31, 2024.
  • John will be an integral member of our team, as we advance our existing assets and evaluate additional opportunities for investment,” said Bill Conkling, CEO of Rafael Holdings.
  • During the second quarter of 2024, we increased our investment in Day Three Labs and now hold a majority interest in the company with 79% of the shares outstanding and began consolidating its financial results in the second quarter of 2024.
  • During the second quarter of 2024, we increased our investment in Day Three Labs and now hold a majority interest in the company with 79% of the shares outstanding and we began reporting consolidated its financial results in January 2024.

Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Retrieved on: 
Wednesday, March 13, 2024
YTD, Drug development, Sale, ENZ, Corporation, Fine chemical

FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024.

Key Points: 
  • FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024.
  • During the 2024 period, we experienced a 25% revenue increase in the United States, driven by increased product demand in the drug development and cell and gene therapy market segments.
  • Revenue for the six months ended January 31, 2024 of $16.4 million improved 12% compared to the same period in the prior year.
  • The six-month YTD margin was 47% which was also a 1,000 basis point improvement compared to the prior year.

3Daughters Announces Three New Appointments to Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
Quotient, Thakeham, Alnylam Pharmaceuticals, CDMO, Birth, Labs, GSK plc, Pharmacy, University, Novartis, Dana–Farber Cancer Institute, IUD, University College London, Embryology, IND, MBA, Woman, Doctor of Philosophy, Intrauterine device, Therapy, Drug development, Allergan, Amersham plc, Takeda Oncology, Chief Justice of Hungary, Pharmacia, Birth control

Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.

Key Points: 
  • Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.
  • An IND for 3D-001 will be filed this year followed by a Phase 1 clinical trial.
  • Mary Beth Cicero, CEO of 3Daughters, expressed her enthusiasm about the new additions to the board: "We are incredibly excited to have the collective strengths of Michele, Sarah, and Vin on our Board of Directors.
  • With this first product, 3Daughters expects to disrupt the IUD market and establish a position as a major innovator in women's healthcare.

Novotech Publishes Precision Oncology Landscape Whitepaper Identifying Current Trends and Opportunities in Targeted Therapies

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, Checkmate, Prevalence, Patient, World Games, SWOT, Biomarker, Research, NCCN, Cancer, EMA, Contract research organization, National Comprehensive Cancer Network, Protein, Medicine, Clinical trial, Drug development, Therapy, Precision, FDA, Pharmaceutical industry

Precision oncology, or personalized medicine, involves the use of biomarker testing to identify the driver mutations of a patient’s cancer and actionable biomarkers for targeted therapy treatment.

Key Points: 
  • Precision oncology, or personalized medicine, involves the use of biomarker testing to identify the driver mutations of a patient’s cancer and actionable biomarkers for targeted therapy treatment.
  • The Precision Oncology - Global Clinical Trial Landscape whitepaper is designed for researchers, clinicians, pharmaceutical, biopharma and biotech firms.
  • It presents a thorough analysis of healthcare, technology, macroeconomic, regulatory trends, SWOT analysis, funding, and innovative research developments in precision oncology.
  • The report provides a detailed review of the current precision oncology landscape including standout trials, important trends around FDA approvals, funding initiatives, and ongoing insights impacting research and development.

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Retrieved on: 
Wednesday, March 13, 2024
Knee, Congress, Biologics license application, Patient, ATMP, Research, World Congress, OARSI, European Medicines Agency, WOMAC, Osteoarthritis Research Society International, KOOS, Drug development, Safety, Pain, Vasopressin receptor 2, DVD-Audio, Food, Osteoarthritis, FDA, BLA, Pharmaceutical industry

TAMPA, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 (enekinragene inzadenovec), the company’s novel, intra-articular helper-dependent adenovirus (HDAd) gene therapy product candidate that codes for interleukin-1 receptor antagonist (IL-1Ra), for the treatment of osteoarthritis of the knee.

Key Points: 
  • PCRX-201 was well tolerated, with efficacy observed through at least 52 weeks at all doses and cohorts.
  • Preliminary 36-week data were presented at the Osteoarthritis Research Society International (OARSI) 2023 World Congress, the premier annual international forum in osteoarthritis research and treatment.
  • The 52-week data have been accepted for presentation at OARSI 2024 taking place in Vienna, Austria in April 2024 and the company expects to present 104-week efficacy and safety data later this year.
  • PCRX-201 was also granted Advanced Therapy Medicinal Products (ATMP) designation by the European Medicines Agency in May 2023.

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Retrieved on: 
Wednesday, March 13, 2024
Research, Takeda Pharmaceutical Company, IO, Biotechnology, PFM, University, Patient, Columbia University, Cowen Inc., Doctor of Philosophy, Biochemistry, New Enterprise Associates, CFA, Cancer, Texas A&M University, Pfizer, Chemical engineering, Drug development, NEA, Therapy, ADC, Pharmaceutical industry

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.

Key Points: 
  • BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.
  • “We are thrilled to have Santhosh join the Pyxis Oncology board.
  • Santhosh brings a wealth of business, investment, strategic, and board experience to our team,” said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology.
  • "I am delighted to join the Board of Directors at Pyxis Oncology at such a pivotal moment in the Company's journey as they anticipate data readouts for their lead ADC program, PYX-201, and their IO program, PYX-106, in 2024," said Dr. Santhosh Palani.

EverythingALS Launches the Vision 2030 AI Hub: Charting the Path to an ALS Cure and Advancing Neurodegenerative Disease Research

Retrieved on: 
Tuesday, March 12, 2024
Research, Neurology, Harvard Medical School, Synthetic media, Machine learning, Government, Regeneration, Prevalence, Massachusetts General Hospital, Science, Environment, MIT, Data science, SAN, Knowledge, Biomarker, History, Hope, Doctor of Philosophy, LLM, Vision 2030, Hub, Ecosystem, Drug development, Navar, Frontotemporal dementia, Artificial intelligence, Generative, Mass, Medicine, Medical device

The Vision 2030 AI Hub will have a laser focus on "repair and regeneration," aiming to distinguish the organization in the ALS research landscape.

Key Points: 
  • The Vision 2030 AI Hub will have a laser focus on "repair and regeneration," aiming to distinguish the organization in the ALS research landscape.
  • The Vision 2030 AI Hub epitomizes this momentous convergence—where the cumulative advances in ALS research and technology coalesce, heralding a new epoch of hope and discovery.
  • The Vision 2030 AI Hub motivates giving and fundraising, showcasing an innovative operating model that emphasizes urgency in tackling ALS and other disorders.
  • For more information about EverythingALS, Vision 2030, and the AI Hub visit http://www.v2030.org or email us at [email protected] .